Moderna made headlines in 2021 with a commitment to bringing more mRNA manufacturing capabilities to Africa, eventually landing on Kenya as the site of a $500 million plant project. Now, amid waning global vaccine demand, the company has hit pause on the endeavor.
The Spikevax maker is taking a step back to evaluate future demand for mRNA vaccines in Africa as it has not received any vaccine orders from the continent since 2022, Moderna said in a statement.
Cancelations of previous orders have stacked up to “more than $1 billion” in losses and write-downs, according to the mRNA specialist. The company said demand "has declined since the pandemic and is insufficient to support the viability of the factory planned in Kenya."
Too bad - I was looking forward to the start of biopharma manufacturing in Africa. Here's hoping for brighter days.
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20